Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients

This study will evaluate the use of a prasugrel 60 mg loading dose (LD) administered during
percutaneous coronary intervention (PCI) with and without a prior LD of clopidogrel on
platelet inhibition in patients presenting with ACS. Platelet inhibition following a
prasugrel LD in clopidogrel pretreated patients' will be determined in a time-dependent
manner for two different prasugrel loading doses (30 mg and 60 mg). Understanding the
effects of this combination on platelet inhibition will provide guidance to physicians on
the use of prasugrel in patients who have already been pretreated with clopidogrel.